Survivin Inhibition Enhances Apoptosis in Liver Cancer Cells
Author Information
Author(s): Zhao Xiangxuan, Ogunwobi Olorunseun O., Liu Chen
Primary Institution: University of Florida
Hypothesis
The study aims to investigate the therapeutic effects of the Bcl-2 inhibitor ABT-263 on hepatocellular carcinoma (HCC) and the role of survivin inhibition in enhancing apoptosis.
Conclusion
The combination of ABT-263 and the survivin inhibitor YM-155 significantly induces apoptosis in HCC cells without harming normal human hepatocytes.
Supporting Evidence
- ABT-263 alone did not induce apoptosis in HCC cells at low doses.
- The combination of ABT-263 and YM-155 resulted in significant apoptosis in HCC cells.
- Survivin inhibition through gene silencing enhanced ABT-263-induced apoptosis.
Takeaway
This study found that a special cancer drug works better when combined with another drug that stops a protein called survivin, which helps cancer cells survive.
Methodology
The study involved treating HCC cell lines with ABT-263 and YM-155, assessing apoptosis through Hoechst staining and Western blotting for caspase activation.
Potential Biases
Potential bias in the selection of cell lines and treatments used.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Participant Demographics
Liver cancer tissues from more than 10 different patients were analyzed.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website